Related Experiment Video
Updated: Aug 12, 2026
Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter
Published on: August 12, 2021
Treatment for Severe Coronavirus Disease 2019 With the Seraph-100 Microbind Affinity Blood Filter
Stephen W Olson1,2, James D Oliver1,2, Jacob Collen2
1Nephrology Service, Walter Reed National Military Medical Center, Bethesda, MD.
Insights
Seraph-100 treatment may stabilize hemodynamics in severe COVID-19 patients on mechanical ventilation and vasopressors. This novel device showed reduced vasopressor needs and inflammatory markers in early cases.
Area of Science:
- Medical Devices
- Infectious Diseases
- Critical Care Medicine
Background:
- Severe coronavirus disease 2019 (COVID-19) often necessitates mechanical ventilation and vasopressor support.
- The Seraph-100 device is a novel extracorporeal treatment investigated for severe COVID-19.
Observation:
- The first two patients in the U.S. receiving Seraph-100 treatment for severe COVID-19 were analyzed.
- Data included vasopressor dose, mean arterial pressure, temperature, and inflammatory biomarkers (IL-6, CRP) pre- and post-treatment.
Findings:
- Seraph-100 treatment was associated with decreased vasopressor requirements, lower temperature, and reduced levels of interleukin-6 and C-reactive protein.
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viremia cleared in the one patient tested after treatment.
Implications:
- Seraph-100 may offer clinical benefit by improving hemodynamic stability in critically ill COVID-19 patients.
- Further research with larger cohorts is needed to confirm these findings and assess impact on mortality and hospital stay.
Abstract:
To determine whether Seraph-100 (Exthera Medical Corporation, Martinez, CA) treatment provides clinical benefit for severe coronavirus disease 2019 cases that require mechanical ventilation and vasopressor support.
Data Sources:
The first two patients in the United States treated with the novel Seraph-100 device. These cases were reviewed by the Food and Drug Administration prior to granting an emergency use authorization for treatment of coronavirus disease 2019.
Study Selection:
Case series.
Data Extraction:
Vasopressor dose, mean arterial pressure, temperature, interleukin-6, C-reactive protein, and other biomarker levels were documented both before and after Seraph-100 treatments.
Data Synthesis:
Vasopressor dose, temperature, interleukin-6, and C-reactive protein levels declined after Seraph-100 treatments. Severe acute respiratory syndrome coronavirus 2 viremia was confirmed in the one patient tested and cleared by the completion of treatments.
Conclusions:
Seraph-100 use may improve hemodynamic stability in coronavirus disease 2019 cases requiring mechanical ventilation and vasopressor support. These findings warrant future study of a larger cohort with the addition of mortality and total hospital day outcomes.
More Related Videos
Related Concept Videos
01:29Coronavirus
01:29Respiratory Syncytial Virus Disease